News and Trends 29 Sep 2025 First-ever approval for Barth Syndrome treatment: what does this mean for ultra-rare disease therapeutics? FDA approval for Stealth BioTherapeutics’ elamipretide has been a long time coming. What does this mean for other ultra-rare disease companies? September 29, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
More News! 27 Aug 2025 Zemcelpro, the first blood cord expansion therapy to reach the EU market Find out about ExCellThera’s zemcelpro, the first blood cord expansion therapy to reach the European market, and only the second globally. August 27, 2025 - 6 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 30 Jul 2025 Targeting orexin: the future of narcolepsy treatments There are a few new narcolepsy treatments being tested in the clinic, and recently, some of them have made promising strides. But how far along are they? July 30, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jun 2025 First antibiotic in 50 years to tackle superbug nears approval: what’s going on in the field? Antibiotic development has seen a slump in recent decades. Now, after 50 years, a new antibiotic has been created to tackle bacterial infections. June 9, 2025 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Expert Advice 15 May 2025 Expert tips to choose the right CDMO for your biotech company Find out the best way to find the right CDMO for your biotech. Experts shared some advice to help companies through the process. May 15, 2025 - 11 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 12 Mar 2025 Checkpoint inhibitors in cancer: breakthroughs, setbacks, and what’s next Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field. March 12, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 Feb 2025 Rare Disease Day: seven drugs awaiting approval in 2025 As we observe Rare Disease Day today, let us take a look at seven drugs poised to be approved to address rare diseases in 2025. February 28, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 27 Jan 2025 Top 19 most-performing biotech stocks of 2024 Discover the top-performing biotech stocks in 2024 – from oncology to psychedelics some companies showed remarkable results. January 27, 2025 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 16 Jan 2025 Ten first-in-class drugs on track for FDA approval in 2025 As the year unfolds the biotech industry will look closely at these ten first-in-class drugs on track to reach FDA approval in 2025. January 16, 2025 - 13 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 8 Jan 2025 Ten drugs to watch in 2025: will these therapies become blockbusters? Here are some of the drugs that are predicted to become blockbusters in the next few years, according to Clarivate’s latest report. January 8, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 2 Oct 2024 Niemann-Pick disease: FDA approves first two drugs in the space of a week for rare disorder Find out all about the first two FDA drug approvals for the rare genetic disorder Niemann-Pick disease type C. October 2, 2024 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 11 Sep 2024 Can Europe revive its biopharma innovation leadership? Find out if the biotech runner-up, Europe, can step up to boost research and revive its innovation leadership. September 11, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email